Skip to main content
OpenTrials
Completed

NCT Number: NCT06867055

Evaluation of the Effectiveness of Different Procedures on Palatinal Wound Healing After Free Gingival Graft Surgery.

This study aimed to help determine the appropriate method to accelerate wound healing at the free gingival graft donor site and to minimize the patient's postoperative complaints. For this purpose, gelatin sponge impregnated with injectable platelet-rich fibrin (I-PRF), gelatin sponge impregnated with 0.8% polyvinylpyrrolidone sodium hyaluronate (HA) gel, and standard gelatin sponge application were compared to the secondary wound site on the palate.

The main questions aimed at being answered are:

* Does the use of I-PRF or HA accelerate wound healing in patients? * Does the use of I-PRF or HA reduce pain and burning symptoms? * For this purpose, gelatin sponge impregnated with injectable platelet-rich fibrin (I-PRF), gelatin sponge impregnated with 0.8% polyvinylpyrrolidone sodium hyaluronate (HA) gel, and standard gelatin sponge application were compared to the secondary wound site on the palate.

Participants will:

* They will record whether there is pain and burning for 7 days after the operation. * They will record if there is bleeding in the palate area. * They will write the number of painkillers they use daily. * They will visit the clinic on the 3rd, 5th, 7th, 14th, 21st, 28th days and 1st and 3rd months after the operation.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–58 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Health Sciences University Gulhane Faculty of Dentistry

Ankara, (533) 316-1232, Turkey (Türkiye)

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Inclusion criteria for the study were;
  • patients older than 18 and
  • systemically healthy patients,
  • who didn't use drugs that affect wound healing,
  • didn't have coagulation disorder and nausea, and
  • were not anti-inflammatory drug allergy sufferers.

Exclusion criteria

  • Exclusion criteria for the study were;
  • patients who had systematic disorders (such as diabetes, hypertension, radiotherapy, chemotherapy),
  • patients who were former or active smokers and alcohol users,
  • pregnant and breastfeeding, lactation, menstruation,
  • patients with poor oral hygiene, and patients who didn't attend regular check-ups.

Treatment and study plan

Injectable Platelet-Rich Fibrin (i-PRF)

Biological

I-PRF were produced with 11-mL plastic tubes (16*10 mm) using a Nuve NF 200 centrifugation device with a rotor angulation with a radius of 101 mm at the clot (Nuve NF 200, Nuve Industrial Materials Manufacturing and Trade Company, Ankara, Türkiye). The I-PRF at the top of the tube was collected with a syringe and transferred to the metal bowl. It was held for 20-25 min for polymerization.

0.8% hyaluronic acide (HA)

Drug

0.8% polyvinylpyrrolidone sodium hyaluronate (HA) (Gengigel Prof, Ricerfarma SRL.) gel was impregnated on a sterile gelatin sponge and sutured with 4/0 silk suture (4/0 Sterisilk, SSM Medical Equipment, Türkiye) on the palate area and bleeding control was provided with SX bioplast plate.

Control Group

Other

Sterile gelatin sponge was sutured with 4/0 silk suture (4/0 Sterisilk, SSM Medical Equipment, Turkey) in the palatal region where FGG was taken and bleeding was controlled with SX bioplast plate.

Primary outcomes

  1. Landry Wound Healing Index (WHI)

    Time frame: 1st, 3rd, 7th, 14th, 21st, 28th days and 1st and 3rd month after the surgical procedure

    The primary result expected from the study is that the healing of the palatinal region left for secondary healing is faster in the I-PRF and 0.8% HA groups compared to the control group.

    The primary outcome of the study was to measure the palatal wound healing status using the Landry Wound Healing Index (WHI) (Landry RG (1985) Efectiveness of benzydamine HC1 in the treatment of periodontal post-surgical patients. Faculty of Dentistry, University of Toronto), which grades the wound healing on a scale of the 3rd, 7th, 14th, 21st, and 28th days postoperatively. This index, which has a score range of 1 (very poor) to 5 (excellent), evaluates tissue color, response to palpation, granulation tissue presence, incision margins' epithelialization, and amount of suppuration.

Secondary outcomes

  1. pain and burn (Visual Analog Scale)

    Time frame: First 7 day after the surgical procedure

    The secondary result expected from the study is that postoperative pain and burning are less in the I-PRF and 0.8% HA groups compared to the control group.

    The secondary outcomes of the study were to measure patients' perception of pain, discomfort while chewing, and burning sensation after FGG harvesting using a numerical rating scale (VAS) from 0 (no pain, no discomfort while chewing, no burning sense) to 10 (the worst pain imaginable, extreme discomfort while chewing, extreme burning sense) between days 1 and 7, and the amount of analgesic consumption between days 1 and 7 postoperatively.

  2. Tissue color match (CM)

    Time frame: 1st, 3rd, 7th, 14th, 21st, 28th days and 1st and 3rd month after the surgical procedure

    Tissue color match (CM) was assessed with adjacent and contralateral palatal tissue (0-no color matching to 10-excellent color matching)

  3. postoperative bleeding

    Time frame: 1st, 3rd, 5th, and 7th day after the surgical procedure.

    The patients were asked to keep a record of whether there was any bleeding in the palatal region, and at the same time, the presence of postoperative bleeding, also known as delayed bleeding (DB), was recorded as present (+) or absent (-) on the days when the patients came to the follow up appointments.

  4. H2O2 bubbling

    Time frame: 1st, 3rd, 7th, 14th, 21st, 28th days after the surgical procedure

    The epithelialization of the palatal region was recorded according to the application of 3% hydrogen peroxide to the region and whether there was foaming or not, and was calculated as a percentage (H2O2 bubbling). Complete epithelization (CE) was also evaluated clinically by monitoring the surface characteristics and clarity of the wound contour and recorded as "yes" or "no".

  5. Oral Health Related Quality of Life (OHRQoL)

    Time frame: 7th and 14th days after the surgical procedure.

    Oral Health Related Quality of Life (OHRQoL) was administered on the 7th and 14th days after the surgical procedures to analyse how the person's daily physical-social life and mental health status were affected. This scale developed by McGrath and Bedi evaluates the effects of oral health on quality of life in both positive and negative domains. The scale includes 16 questions consisting of 4 different categories. The categories consist of current symptoms (2 questions) and physical (5 questions), psychological (5 questions) and social (4 questions) conditions. The questions in the OHRQOL-TR questionnaire are scored on a Likert scale with values between 1 and 5 (such as 'very bad' (score 1), 'bad' (score 2), 'none' (score 3), 'good' (score 4) or 'very good' (score 5)). When the scores of 16 questions are totalled, there is a value in the range of 16-80. The reliability and validity of the Turkish version of the scale was proved and reported in the study conducted by Mumcu et al.

  6. Number of analgesics taken

    Time frame: First 7 day after the surgical procedure.

    Patients were informed that the number of analgesics theytook for post-operative pain relief was recorded for 7 days

  7. palatal soft-tissue thickness (PSTT)

    Time frame: Initial, 1st and 3rd month after the surgical procedure

    The PSTT in the harvested area was measured after theadministration of local anaesthesia.The measurement was made approximately 5 mm apical to the gingival marginof the first premolar using a #15 endodontic reamer. Thepenetration depth was measured using a digital caliper. Themeasurements were obtained before harvesting the FGG and at 1 and 3 months after the operation.The graft thickness was measured in the same way at the middle points of all four edges of the graft. The mean of theobtained values was calculated and considered to be the graft thickness. The dimensions of the graft were standardized using a sterile aluminium foil template of 7 * 12 mm.

  8. tissue consistency

    Time frame: On the 3rd, 7th, 14th and 21st days after surgery

    After the operation, the consistency of the donor area in the palatal region was marked to be soft and firm.

  9. Palate sensitivity

    Time frame: On the 7th, 14th and 21st days after surgery

    Palate sensitivity was measured by using a numerical rating scale (VAS) from 0 (no sensitivity) to 10 (most sensitivity) on the 7th, 14th and 21st days after surgery

  10. Loss of sensation

    Time frame: n the 3rd, 7th, 14th, 21st, 28th day, 1st month, and 3rd month after the operation

    Loss of sensation was recorded as none (0), moderate (1), and severe (2) on the 3rd, 7th, 14th, 21st, 28th day, 1st month, and 3rd month after the operation.

Sponsors and collaborators

Lead sponsor

SEVAL CEYLAN ŞEN

Other

Collaborators

  • İNCİ PHARMA

Registry information

Official study title

Evaluation of the Efficacy of Injectable Platelet Rich Fibrin (I-TZF) Impregnated Gelatin Sponge and 0.8% Hyaluronic Acid Gel Impregnated Gelatin Sponge on Clinical Healing of Palatinal Wound Healing After Free Gingival Grafting.

Important dates

Study start
2023
Primary completion
2025
Study completion
2025
First posted
Mar 10, 2025
Registry last updated
Mar 4, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.